The place of thalidomide in the treatment of inflammatory disease.
Stevens
R J
RJ
D000014:Abnormalities, Drug-Induced / Q000517:prevention & control; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D000075202:Contraindications; D016207:Cytokines / Q000096:biosynthesis; D003872:Dermatitis / Q000188:drug therapy; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007249:Inflammation / Q000188:drug therapy*; D009498:Neurotoxins / Q000009:adverse effects / Q000627:therapeutic use; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy; D012867:Skin / Q000294:innervation; D013792:Thalidomide / Q000009:adverse effects / Q000627:therapeutic use*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016207:Cytokines; D007166:Immunosuppressive Agents; D009498:Neurotoxins; D013792:Thalidomide